Mutated TP53 peptide–MHC class I complex

A mutated TP53 peptide–MHC class I complex is formed when a tumor-derived p53 peptide, containing a cancer-specific mutation, is processed and presented on the surface of tumor cells in the context of an MHC class I (e.g., HLA-A*02:01) molecule. This peptide–MHC complex acts as a neoantigen, rendering the mutated p53 protein visible to T cells, and can be specifically targeted by engineered bispecific antibodies, TCR mimic antibodies, or adoptive cell therapies. These approaches leverage the immune system to differentiate tumor cells from normal cells by recognizing the unique peptide–MHC signature associated with TP53 mutations, with the goal of selective tumor cell elimination. Therapeutic development is challenged by low levels of complex expression and risks of cross-reactivity, but such complexes are increasingly recognized as highly specific drug targets for cancers harboring recurrent TP53 mutations[3][5][7].

Other names

Mutated p53 peptide–HLA complexMutant p53 peptide–MHC complexMutant TP53 neoantigen–MHC I complex

Redirect T cells to mutant p53-expressing tumor cells via recognition of the peptide–MHC complex[7] Antibody- or TCR-based recognition of surface peptide–MHC for targeted cell killing[3][7] Internalization and lysosomal trafficking upon antibody binding (potentially for ADC delivery)[3]